marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-07-2024
Relmada Therapeutics Balance Sheet 2011-2024 | RLMD
Annual Balance Sheet Relmada Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | - | - | -2.5 M | -8.85 M | 703 K | -1.43 M | -8.23 M | -22.2 M | -25.5 M | -15.3 K | -8.95 K | - |
Long Term Debt |
- | - | - | - | - | 2.66 M | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 2.66 M | - | 141 K | - | 100 K | - | - | - |
Total Current Liabilities |
12.2 M | 12.5 M | 15.1 M | 12.6 M | 1.46 M | 5.9 M | 1.38 M | 3.06 M | 15.6 M | 26.8 M | 21.5 M | - | - |
Total Liabilities |
12.2 M | 12.5 M | 15.1 M | 12.6 M | 2.61 M | 8.56 M | 1.38 M | 3.2 M | 15.6 M | 26.9 M | 33.7 K | 7 K | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-561 M | -462 M | -305 M | -179 M | -112 M | -94.3 M | -85.4 M | -79.1 M | -76.1 M | -55.3 M | -57.2 K | -12.1 K | - |
Total Assets |
97.6 M | 153 M | 223 M | 118 M | 10.2 M | 3.05 M | 2.84 M | 10.2 M | 24.4 M | 25.8 M | 20 K | 18.4 K | - |
Cash and Cash Equivalents |
4.09 M | 5.4 M | 44.4 M | 2.5 M | 36.3 M | 2.43 M | 1.71 M | 8.5 M | 22.5 M | 25.6 M | 3.52 M | 1.77 M | 21.9 K |
Book Value |
85.4 M | 140 M | 208 M | 106 M | 7.61 M | -5.51 M | 1.46 M | 7.04 M | 8.81 M | -1.11 M | -13.7 K | 11.4 K | - |
Total Shareholders Equity |
85.4 M | 140 M | 208 M | 106 M | 116 M | 1.43 M | 1.46 M | 7.04 M | 8.81 M | -1.11 M | -17.9 M | -3.71 M | -2.84 M |
All numbers in USD currency
Quarterly Balance Sheet Relmada Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
8.1 M | - | 12.4 M | 12.2 M | - | - | 10.1 M | 12.5 M | - | - | 15.4 M | 15.1 M | - | - | - | 12.6 M | - | - | - | 1.46 M | 2.54 M | 2.61 M | 2.61 M | 1.86 M | 10.3 M | 8.56 M | 8.56 M | 5.85 M | 4.15 M | 1.38 M | 1.38 M | 1.55 M | 2.35 M | 3.2 M | 3.2 M | 4.84 M | 15.6 M | 15.6 M | 25.4 M | 28.2 M | 48.6 M | 26.9 M | 26.9 M | 21.6 M | - | - | - | 5.71 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-622 M | -600 M | -583 M | -561 M | -536 M | -514 M | -488 M | -462 M | -424 M | -385 M | -345 M | -305 M | -271 M | -228 M | -202 M | -179 M | -179 M | -179 M | -179 M | -120 M | -120 M | -120 M | -120 M | -105 M | -97.7 M | -94.3 M | -94.3 M | -87.8 M | -86.4 M | -85.4 M | -85.4 M | -81.8 M | -80.7 M | -79.1 M | -79.1 M | -73.9 M | -71.5 M | -76.1 M | -76.1 M | -79.7 M | -55.3 M | -55.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
55.7 M | 71 M | 84.4 M | 97.6 M | 109 M | 122 M | 136 M | 153 M | 187 M | 216 M | 226 M | 223 M | 90.9 M | 111 M | 104 M | 118 M | 118 M | 118 M | 118 M | 117 M | 117 M | 117 M | 117 M | 3.3 M | 1.56 M | 3.05 M | 3.05 M | 6.57 M | 5.61 M | 2.84 M | 2.84 M | 6.23 M | 7.92 M | 10.2 M | 10.2 M | 16.6 M | 20.5 M | 24.4 M | 24.4 M | 32.8 M | 27.8 M | 25.8 M | 25.8 M | 3.63 M | 20 K | 4.73 K | 12.3 K | 1.99 M | 18.4 K | 18.4 K | - | - | - | - | - |
Cash and Cash Equivalents |
1.48 M | 2.09 M | 1.34 M | 4.09 M | 6.7 M | 14.5 M | 28.9 M | 5.4 M | 42.5 M | 37.3 M | 44.9 M | 44.4 M | 11.4 M | 4.67 M | 3.8 M | 2.5 M | 7.54 M | 2.5 M | 2.5 M | 36.3 M | 36.3 M | 36.3 M | 36.3 M | 2.43 M | 887 K | 2.43 M | 887 K | 5.94 M | 4.68 M | 5.94 M | 4.68 M | 4.71 M | 6.22 M | 4.71 M | 6.22 M | 15.1 M | 19.2 M | 15.1 M | 19.2 M | 31.4 M | 27.4 M | 31.4 M | 27.4 M | 3.52 M | 3.95 M | 1.56 M | 1.37 M | 1.77 M | 8.95 K | 8.95 K | 4.78 K | 21.9 K | 3.01 K | - | - |
Book Value |
47.6 M | - | 72 M | 85.4 M | - | - | 125 M | 140 M | 187 M | 216 M | 210 M | 208 M | 90.9 M | 111 M | 104 M | 106 M | 118 M | 118 M | 118 M | 116 M | 115 M | 115 M | 115 M | 1.43 M | -8.74 M | -5.51 M | -5.51 M | 721 K | 1.46 M | 1.46 M | 1.46 M | 4.67 M | 5.57 M | 7.04 M | 7.04 M | 11.8 M | 4.9 M | 8.81 M | -963 K | 4.59 M | -20.7 M | -1.11 M | -1.11 M | -17.9 M | 20 K | 4.73 K | 12.3 K | -3.71 M | 18.4 K | 18.4 K | - | - | - | - | - |
Total Shareholders Equity |
47.6 M | 61.5 M | 72 M | 85.4 M | 101 M | 111 M | 125 M | 140 M | 166 M | 197 M | 210 M | 208 M | 72.7 M | 96.9 M | 91.1 M | 106 M | 106 M | 106 M | 106 M | 116 M | 116 M | 116 M | 116 M | 1.43 M | 1.43 M | 1.43 M | -8.74 M | 721 K | 1.46 M | 721 K | 1.46 M | 4.67 M | 5.57 M | 7.04 M | 7.04 M | 11.8 M | 13.8 M | 8.81 M | 8.81 M | 4.59 M | -20.7 M | -1.11 M | -1.11 M | -17.9 M | -13.7 K | -21.3 K | -28 K | -3.71 M | 11.4 K | 11.4 K | - | -2.84 M | 9.91 K | - | - |
All numbers in USD currency